Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

Core Insights - Tevogen Bio Holdings Inc. plans to expand the target population for its product TVGN 489 to include patients aged 65 and older, enhancing its market potential [1] - The top-line revenue forecast for the specialty care pipeline is projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between$18 billion and $22 billion [1] - The expansion aims to address significant unmet medical needs, particularly in light of the new COVID variant NB.1.8.1 [2] Company Developments - Tevogen's Chief Commercial Officer emphasized the importance of expanding clinical manufacturing capacity to meet the demands posed by the new COVID variant [2] - The expanded pipeline will include treatments for SARS-CoV-2 infection in various patient groups, including those with B cell hematologic cancer and patients aged 65 and older [5] Financial Projections - The updated forecast and risk-adjusted net present value (rNPV) will be provided to reflect the inclusion of the 65+ patient population [1] - The anticipated revenue growth reflects the company's strategic focus on specialty pharmaceuticals and addressing broader market needs [1]